Notice: This company has been marked as potentially delisted and may not be actively trading. NASDAQ:CHMA Chiasma (CHMA) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock Analysis About Chiasma Stock (NASDAQ:CHMA) 30 days 90 days 365 days Advanced Chart Ad Crypto Swap Profits625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.>> Dive into the Workshop Here Get Chiasma alerts:Sign Up Key Stats Today's Range$3.76▼$3.7650-Day Range$3.76▼$4.7152-Week Range$2.77▼$5.74Volume147 shsAverage Volume2.12 million shsMarket Capitalization$217.68 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewChiasma, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing oral medications using transient permeability enhancer technology platform for the treatment of rare and serious chronic disease worldwide. The company offers MYCAPSSA, an oral octreotide capsule for the long-term maintenance treatment in acromegaly patients who have responded to and tolerated treatment with octreotide or lanreotide. It also develops MPOWERED, an oral octreotide capsule, which has completed Phase III clinical trials for the maintenance treatment of adult patients with acromegaly. Chiasma, Inc. was incorporated in 2001 and is headquartered in Needham, Massachusetts.Read More… 625,000% Gain (Ad)Imagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.>> Dive into the Workshop Here Receive CHMA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Chiasma and its competitors with MarketBeat's FREE daily newsletter. Email Address CHMA Stock News HeadlinesChiasma Craters on FDA Drug RejectionOctober 29, 2023 | thestreet.comOrphan Drugs Market Size to Hit USD 340.84 Billion by 2027 - GlobeNewswireOctober 6, 2022 | globenewswire.comSell NVDA Now?Guess who's selling NVDA next The most successful hedge fund in history quietly sold 500,000 shares. Here's what that means for your money. Billionaire Wall Street investors are quietly offloading millions of shares. What do they know that you don't? It's arguably the most popular stock in the world. Now, one 50-year Wall Street legend says its day in the sun could finally be coming to an end. Last year, he warned of two stocks that went on to crash 60%.November 2, 2024 | Chaikin Analytics (Ad)Ironshore Announces Executive Appointments and Strengthening of the Global Business Management Team - Business WireSeptember 28, 2022 | businesswire.comCHMP adopts positive opinion for Mycapssa® for the treatment of Acromegaly - Marketscreener.comSeptember 16, 2022 | marketscreener.comAmryt (AMYT) Receives Positive CHMP Opinion for Mycapssa - StreetInsider.comSeptember 16, 2022 | streetinsider.comAmryt to Present Data from MPOWERED Phase 3 Trial of Mycapssa® (oral octreotide) at ENEA 2022 - Yahoo Finance UKSeptember 7, 2022 | uk.finance.yahoo.comMPM ASSET MANAGEMENT LLC Buys - GuruFocus.comAugust 12, 2022 | gurufocus.comSee More Headlines CHMA Stock Analysis - Frequently Asked Questions How were Chiasma's earnings last quarter? Chiasma, Inc. (NASDAQ:CHMA) posted its quarterly earnings data on Thursday, May, 6th. The biotechnology company reported ($0.49) earnings per share for the quarter, missing the consensus estimate of ($0.31) by $0.18. The biotechnology company earned $1.92 million during the quarter, compared to analysts' expectations of $1.80 million. When did Chiasma IPO? Chiasma (CHMA) raised $76 million in an IPO on Thursday, July 16th 2015. The company issued 5,400,000 shares at a price of $13.00-$15.00 per share. Barclays and Cowen and Company served as the underwriters for the IPO and William Blair and Oppenheimer & Co. were co-managers. What other stocks do shareholders of Chiasma own? Based on aggregate information from My MarketBeat watchlists, some other companies that Chiasma investors own include Arbutus Biopharma (ABUS), Bausch Health Companies (BHC), Meta Platforms (META), GW Pharmaceuticals (GWPH), Sorrento Therapeutics (SRNE), SCYNEXIS (SCYX) and TherapeuticsMD (TXMD). Company Calendar Last Earnings5/06/2021Today11/02/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical Preparations Sub-IndustryN/A Current SymbolNASDAQ:CHMA CUSIPN/A CIK1339469 Webwww.chiasmapharma.com Phone617-928-5300FaxN/AEmployees85Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($1.43) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-74,780,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-113.57% Return on Assets-57.62% Debt Debt-to-Equity RatioN/A Current Ratio7.91 Quick Ratio7.08 Sales & Book Value Annual Sales$1.11 million Price / Sales196.11 Cash FlowN/A Price / Cash FlowN/A Book Value$1.59 per share Price / Book2.36Miscellaneous Outstanding Shares57,894,000Free FloatN/AMarket Cap$217.68 million OptionableNot Optionable Beta1.28 Social Links A Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for November 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.Get This Free Report This page (NASDAQ:CHMA) was last updated on 11/2/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | SponsoredEx WH Advisor Who Predicted Biden Leaving Race Makes Startling New PredictionFormer advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | SponsoredSell NVDA Now?Guess who's selling NVDA next The most successful hedge fund in history quietly sold 500,000 shares. Here's...Chaikin Analytics | SponsoredMarket "Famine" ComingMarket Wizard Larry Benedict accurately predicted that all indexes would be negative in 2022... He predicte...Opportunistic Trader | SponsoredBlackrock’s Sending THIS Crypto Higher on PurposeIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredNvidia warning urgentI thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredNothing can stop this gold rallyAfter what's felt like nearly a decade of disappointing gains, gold is stronger than ever and continues to hit...Stansberry Research | SponsoredWall St. Legend: Millions of Americans About to Fall Out of the 1%Wall Street insider reveals the financial tidal wave about to knock millions of Americans out of the One Perce...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Chiasma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Chiasma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
